Sign in
← Database
Senolytic Peptide

FOXO4-DRI

Shop · Omnichems ↗Buy · Disguised Alpha ↗
Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

A rationally designed peptide intended to selectively kill senescent cells by disrupting a FOXO4-p53 interaction; evidence is largely preclinical, and there are no approved human uses.

How it works

FOXO4-DRI is an experimental peptide built to target "senescent" cells — aged, damaged cells that stop dividing but linger in tissue and secrete inflammatory signals thought to contribute to aging and age-related disease. The idea is to remove these cells selectively while sparing healthy ones, an approach called "senolysis."

The peptide is a modified fragment of the FOXO4 protein engineered with D-amino acids (a mirror-image "retro-inverso" design) to make it more stable and to act as a decoy. In senescent cells, FOXO4 helps keep the tumor-suppressor protein p53 sequestered in the nucleus, which keeps those cells alive despite their damage. The peptide is designed to break up that FOXO4-p53 partnership, freeing p53 to trigger programmed cell death (apoptosis) preferentially in senescent cells.

It is important to be clear about the state of evidence: FOXO4-DRI is a research tool. The headline findings come from cell-culture and mouse studies; rigorous human clinical data are lacking. Claims about reversing aging or restoring youthful function in people are not established, and safety, dosing, and long-term effects in humans are unknown.

Mechanism · Detailed Analysis
Molecular targetFOXO4-DRI is a retro-inverso D-amino-acid peptide derived from a FOXO4 sequence. Its proposed action is to competitively interfere with the interaction between FOXO4 and p53, a complex reported to help retain p53 in the nucleus and suppress apoptosis in senescent cells.
Signaling & downstream effectsBy disrupting FOXO4-p53 binding, the peptide is intended to permit p53 to relocalize (including to mitochondria) and activate intrinsic apoptotic pathways. The hypothesized selectivity rests on senescent cells being more dependent on this FOXO4-mediated survival mechanism than normal cells, so that healthy cells are relatively spared. This selectivity is a proposed mechanism, not a fully validated one in humans.
Evidence & development statusReported activity is largely from in-vitro and rodent experiments. FOXO4-DRI is not an approved drug, has no established human pharmacokinetic profile, and is sold only as a research chemical. Robust, peer-validated human efficacy and safety data are absent.
CaveatsPromoting p53-driven apoptosis is a double-edged mechanism, and off-target or systemic effects in humans are not characterized. Peptide stability, delivery, biodistribution, and immune responses remain open questions. Anti-aging or therapeutic claims for humans are unsupported by adequate clinical evidence.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.